Clinical trials: Metastatic Neuroendocrine Neoplasm
Carcinoid Syndrome, Carcinoid Tumor
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors.
- Conditions
- Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor
- Trial name
- NCT04993261
- Testing
- Dual-Energy Computed Tomography
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes by DEC-C during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+…
- Trial name
- NCT05089370
- Testing
- Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 10 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Melanoma Metastatic
Interleukin-2 in Metastatic Melanoma
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
- Trial name
- NCT01702896
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Western Regional Medical Center
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
- Trial name
- NCT04987996
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Sponsor
- Providence Health & Services
Melanoma, Malignant Melanoma
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
The purpose of this research study is to see if the study drug, CT-011, is safe to give and if it helps people with melanoma that has spread to other areas of their body. CT-011 is a monoclonal antibody.
- Trial name
- NCT01435369
- Testing
- CT-011
- Where
- 18 sites in United States, Israel
- Volunteers
- 103 people
- Sponsor
- Medivation, Inc.
Metastatic Melanoma
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and…
- Trial name
- NCT04109456
- Testing
- IN10018, Cobimetinib, Atezolizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Neuroendocrine Tumors, Pancreatic Neoplasms
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
- Trial name
- NCT02402062
- Testing
- TH-302 + Sunitinib
- Where
- 10 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Melanoma, Metastatic Melanoma
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma.
- Trial name
- NCT04930783
- Testing
- CDX-301, NEOVAX, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- NCT03472027
- Testing
- BCD-145
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Recurrent Melanoma, Stage III Melanoma
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white blood cells to kill melanoma cells.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00945269
- Testing
- therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Melanoma
IL2 Imaging in Metastatic Melanoma
T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types.
- Trial name
- NCT02922283
- Testing
- IL2-PET scan, Tumor biopsy, CT scan
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- University Medical Center Groningen
Malignant Melanoma
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
This is a Phase I study looking at the combination of Valproic Acid (VPA) and Karenitecin to treat patients with metastatic malignant melanoma.
- Trial name
- NCT00358319
- Testing
- Karenitecin, Valproic Acid
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma, Head Neck Cancer
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in…
- Trial name
- NCT02521870
- Testing
- SD-101(1), Pembrolizumab, SD-101(2)
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 241 people
- Sponsor
- Dynavax Technologies Corporation
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Melanoma (Skin)
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral…
- Trial name
- NCT00037037
- Testing
- MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Melanoma
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF V600-mutant advanced/metastatic melanoma.
- Trial name
- NCT03878719
- Testing
- binimetinib, encorafenib
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Pfizer
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
- Trial name
- NCT02506153
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 576 sites in United States, Canada and 1 more
- Volunteers
- 1,301 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.
- Trial name
- SBRT/IL-2 (NCT01416831)
- Testing
- Radiation therapy and high-dose IL-2, High-dose IL-2
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Providence Health & Services